FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236414918> ?p ?o ?g. }

• W4236414918 abstract "<h3>Introduction</h3> Hepatitis B reactivation is a potentially life-threatening complication of immunosuppression in patients with serological evidence of current or past exposure to Hepatitis B Virus (HBV). Rituximab is a widely used B-cell depleting medication widely used to treat haematological cancers and rheumatological disease. The British Society of Rheumatology, British Society of Haematology and the European Association of Study of the Liver guidelines all recommend patients must all be assessed for HBV before rituximab initiation. This is a single-centre five-year retrospective review of our Trusts Rituximab prescribing and HBV screening. <h3>Methods</h3> We included all adult patients receiving rituximab between 1st October 2015 and 30th September 2020 at our Trust. Patients were identified using hospital pharmacy Rituximab prescribing logs. Indications, HBV screening bloods and outcomes were collected using electronic records (Allscripts, Telepath). Patients with incomplete or missing records were excluded. <h3>Results</h3> A total of 870 patients were included in this study. Seventy percent (n = 611) were for oncohaematological indications and 30% (n =258) for rheumatological. There were 606 patients newly initiated on Rituximab during the study period (Table 1). HBV screening improved from 62% to 94% during the study period. Eighteen patients were positive or equivocal for Hepatitis B core antibody and 1 for Hepatitis B Surface Antigen. Four patients were prescribed lamivudine prophylaxis, 2 Tenofovir and 1 entecavir. The other patients had no treatment or monitoring. Only 1 case was on adequate length of prophylaxis after being referred to the hepatobiliary service. There were no cases of hepatitis B reactivation in the study period. <h3>Conclusions</h3> A significant number of patients are not being screened for Hepatitis B core antibodies, despite local education programmes in 2016 and 2018. Low background rates of HBV in the local community may account for low levels of previous and current HBV infections. Education of prescribers, modifications to the initiation pharmacy checklists and simplification of computer request process should help to improve Hepatitis B screening in our patients and avoid potentially life-threatening reactivation." @default.
• W4236414918 created "2022-05-12" @default.
• W4236414918 creator A5048120784 @default.
• W4236414918 creator A5053300532 @default.
• W4236414918 creator A5088114840 @default.
• W4236414918 date "2021-11-01" @default.
• W4236414918 modified "2023-09-26" @default.
• W4236414918 title "PWE-33 Rituximab initiation, prescribing and Hepatitis B reactivation: retrospective five-year review" @default.
• W4236414918 doi "https://doi.org/10.1136/gutjnl-2021-bsg.223" @default.
• W4236414918 hasPublicationYear "2021" @default.
• W4236414918 type Work @default.
• W4236414918 citedByCount "0" @default.
• W4236414918 crossrefType "proceedings-article" @default.
• W4236414918 hasAuthorship W4236414918A5048120784 @default.
• W4236414918 hasAuthorship W4236414918A5053300532 @default.
• W4236414918 hasAuthorship W4236414918A5088114840 @default.
• W4236414918 hasBestOaLocation W42364149181 @default.
• W4236414918 hasConcept C104863432 @default.
• W4236414918 hasConcept C126322002 @default.
• W4236414918 hasConcept C167135981 @default.
• W4236414918 hasConcept C187212893 @default.
• W4236414918 hasConcept C203014093 @default.
• W4236414918 hasConcept C2522874641 @default.
• W4236414918 hasConcept C2776175608 @default.
• W4236414918 hasConcept C2777382497 @default.
• W4236414918 hasConcept C2777869810 @default.
• W4236414918 hasConcept C2779338263 @default.
• W4236414918 hasConcept C2780593183 @default.
• W4236414918 hasConcept C2780653079 @default.
• W4236414918 hasConcept C41260117 @default.
• W4236414918 hasConcept C512399662 @default.
• W4236414918 hasConcept C71924100 @default.
• W4236414918 hasConceptScore W4236414918C104863432 @default.
• W4236414918 hasConceptScore W4236414918C126322002 @default.
• W4236414918 hasConceptScore W4236414918C167135981 @default.
• W4236414918 hasConceptScore W4236414918C187212893 @default.
• W4236414918 hasConceptScore W4236414918C203014093 @default.
• W4236414918 hasConceptScore W4236414918C2522874641 @default.
• W4236414918 hasConceptScore W4236414918C2776175608 @default.
• W4236414918 hasConceptScore W4236414918C2777382497 @default.
• W4236414918 hasConceptScore W4236414918C2777869810 @default.
• W4236414918 hasConceptScore W4236414918C2779338263 @default.
• W4236414918 hasConceptScore W4236414918C2780593183 @default.
• W4236414918 hasConceptScore W4236414918C2780653079 @default.
• W4236414918 hasConceptScore W4236414918C41260117 @default.
• W4236414918 hasConceptScore W4236414918C512399662 @default.
• W4236414918 hasConceptScore W4236414918C71924100 @default.
• W4236414918 hasLocation W42364149181 @default.
• W4236414918 hasOpenAccess W4236414918 @default.
• W4236414918 hasPrimaryLocation W42364149181 @default.
• W4236414918 hasRelatedWork W1977362634 @default.
• W4236414918 hasRelatedWork W1998968045 @default.
• W4236414918 hasRelatedWork W2021611242 @default.
• W4236414918 hasRelatedWork W2037780288 @default.
• W4236414918 hasRelatedWork W2094110283 @default.
• W4236414918 hasRelatedWork W2123911621 @default.
• W4236414918 hasRelatedWork W2140505684 @default.
• W4236414918 hasRelatedWork W2413562227 @default.
• W4236414918 hasRelatedWork W2415687686 @default.
• W4236414918 hasRelatedWork W3028757549 @default.
• W4236414918 isParatext "false" @default.
• W4236414918 isRetracted "false" @default.
• W4236414918 workType "article" @default.